atacicept
atacicept: 5 clinical trials tracked.
atacicept evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about atacicept, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (5)
A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)
Primary endpoint: AE profile and results of routine clinical and laboratory tests
A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN
Primary endpoint: Evaluate the effect of atacicept on Gd-IgA1 in patients with IgAN
A Multicenter, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
Primary endpoint: Incidence of adverse events observed during the dosing period
A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)
Primary endpoint: Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Active Lupus Nephritis
Primary endpoint: Renal Response as definedas UPCR ≤0.5 mg/mg, and eGFR ≥60 mL/min/1.73 m^2 or eGFR <60 mL/min/1.73 m^2 with no confirmed decrease from baseline of >20%